| 000 | 01861 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250516214704.0 | ||
| 264 | 0 | _c20141224 | |
| 008 | 201412s 0 0 eng d | ||
| 022 | _a2168-6157 | ||
| 024 | 7 |
_a10.1001/jamaneurol.2014.803 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDonohue, Michael C | |
| 245 | 0 | 0 |
_aThe preclinical Alzheimer cognitive composite: measuring amyloid-related decline. _h[electronic resource] |
| 260 |
_bJAMA neurology _cAug 2014 |
||
| 300 |
_a961-70 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAlzheimer Disease _xdiagnosis |
| 650 | 0 | 4 |
_aAmyloid beta-Peptides _xmetabolism |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xadministration & dosage |
| 650 | 0 | 4 |
_aApolipoprotein E4 _xgenetics |
| 650 | 0 | 4 |
_aClinical Trials as Topic _xstandards |
| 650 | 0 | 4 |
_aCognition Disorders _xdiagnosis |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 | _aEarly Diagnosis |
| 650 | 0 | 4 |
_aExecutive Function _xphysiology |
| 650 | 0 | 4 | _aFeasibility Studies |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHeterozygote |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMemory, Episodic |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeuropsychological Tests _xstandards |
| 650 | 0 | 4 | _aPositron-Emission Tomography |
| 650 | 0 | 4 | _aProdromal Symptoms |
| 650 | 0 | 4 | _aProspective Studies |
| 700 | 1 | _aSperling, Reisa A | |
| 700 | 1 | _aSalmon, David P | |
| 700 | 1 | _aRentz, Dorene M | |
| 700 | 1 | _aRaman, Rema | |
| 700 | 1 | _aThomas, Ronald G | |
| 700 | 1 | _aWeiner, Michael | |
| 700 | 1 | _aAisen, Paul S | |
| 773 | 0 |
_tJAMA neurology _gvol. 71 _gno. 8 _gp. 961-70 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1001/jamaneurol.2014.803 _zAvailable from publisher's website |
| 999 |
_c23878336 _d23878336 |
||